Q3 2026 Ajanta Pharma Ltd Earnings Call Transcript
Key Points
- Ajanta Pharma Ltd (BOM:532331) reported a 20% growth in revenue for the third quarter, showcasing strong business performance.
- The company's return on capital employed stands at 34% and return on net worth at 26%, indicating robust financial health.
- The US generics business saw a significant growth of 52% for the quarter, driven by eight new product launches.
- The India business contributed 31% to total revenue, with a 19% growth in the current quarter, supported by 16 new product launches.
- Ajanta Pharma Ltd (BOM:532331) continues to outperform the Indian pharmaceutical market, with a growth rate of 11% compared to the market's 9%.
- The Asia branded generic business experienced a 9% decline in sales for the quarter, reflecting softer-than-anticipated performance in certain markets.
- Personnel costs increased by 25% for the quarter, primarily due to the addition of medical representatives.
- The Africa institution business saw a moderate degrowth of 6% for the nine-month period.
- The company faced a mark-to-market foreign exchange loss of INR61 crores during the nine months.
- Ajanta Pharma Ltd (BOM:532331) anticipates that the growth in the US business may not be as high in FY27 as it was in FY26.
Ladies and gentlemen, good day, and welcome to the Ajanta Pharma Q3 FY 2026 earnings conference call.(Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you, and over to you, sir.
Good afternoon, everyone, and welcome to Ajanta's earnings call. With me today, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO, Mr. Rajeev Agarwal, our VP, Finance and Investor Relations. I hope all of you have received the results by now.
For the overall business performance, we have now completed the third quarter and first nine months of the current financial year on a strong note. For the quarter, our revenue from the operations grew by 20% and our margins remained resilient despite higher investments in operating expenses.
All our businesses are shaping broadly in line with our plans, and we remain confident about
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
